This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Updated from 2:39 p.m. EDT

Shares of Lifeway Foods (LWAY) were among the best-performing health-related stocks Tuesday, rising 43% after the company said its kefir milk drinks would soon be available for sale at Target (TGT) stores.

The company said that Target will stock the cultured milk drinks in strawberry, raspberry, cherry and banana-strawberry flavors. The first shipment of kefir took place this week, the company said. "We're thrilled that Target will expand the availability of Lifeway's award-winning lowfat kefir to even more customers," Lifeway said. Financial terms of the deal were not disclosed. Shares of Lifeway traded up $3.61 to $12.

Isis Pharmaceuticals (ISIS) rose 15.3% after the company said it would collaborate with Pfizer (PFE) on the development of eye disease treatments using Isis' antisense platform. Isis said it will receive a technology access fee of $1 million, research funding and milestone payments under the multiyear deal. Isis will also receive royalties on the sale of drugs that stem from the collaboration. Pfizer, which will choose the targets of the drugs, will be responsible for clinical development and commercialization of the antisense drugs. Shares of Isis traded up 45 cents to $3.39.

Shares of Applied Biosystems Group (ABI) fell 5.8% after UBS cut its rating on the stock to reduce from neutral. UBS said Applied's poor outlook for organic sales growth, increasing competition and limited merger and acquisition options led to the downgrade. The firm also said that Applied's shares should not trade at a premium to the group's multiple at this time. Shares traded down $1.32 to $21.29.

Impax Laboratories (IPXLE) said late Monday that it received another delinquency notice from Nasdaq officials on May 17, this time for failure to file its first-quarter report with the Securities and Exchange Commission in a timely manner.

In April, Impax received a Nasdaq notice of potential delisting because the company failed to file its annual report on time. On May 19, the company appeared at a hearing before the Nasdaq Listing Qualifications Panel. The company is hoping Nasdaq will look favorably upon its request to maintain its continued listing. The company has not received any decision from Nasdaq since its May 19 hearing. Shares traded up 16 cents to $15.75.

Other health-care volume movers included Eyetech Pharmaceuticals (EYET), down $11.02 to $12.95; Able Laboratories (ABRX), down $1.30 to $3.75; Pfizer, up 8 cents to $28.84; Elan (ELN), down 2 cents to $7.21; Genentech (DNA), up $2 to $78.60; QLT (QLTI), down $1.55 to $10.25; Guidant (GDT), down 48 cents to $73.75; Johnson & Johnson (JNJ), up 34 cents to $67.60; Merck (MRK), up 11 cents to $32.74; Amgen (AMGN), up 42 cents to $62.53; Aastrom Biosciences (ASTM), down 15 cents to $2.67; and Schering-Plough (SGP), up 15 cents to $20.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs